283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Shubham Pant; Amishi Shah; Pavlos Msaouel; Matthew Campbell; Shi-Ming Tu; Jianjun Gao; George Blumenschein; Frank Mott; Xiuning Le; Mehmet Altan; Funda Meric-Bernstam; Timothy Yap; Vivek Subbiah; Jordi Rodon; Axel Glasmacher; Imke Mulder; Michael Chisamore; Alexander Stevenson; Nizar Tannir

doi:10.1136/jitc-2020-SITC2020.0283

Citation Tools

Regular and young investigator award abstracts

Clinical trials completed

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Pant S, Shah A, Msaouel P, et al

283 Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0283

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password